AGP Picks
View all

Verluma market forecast points to growth in cancer imaging demand

Nov. 19, 2026
Verluma market forecast points to growth in cancer imaging demand
By AI, Created 14:00 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Verluma market is expanding on the back of rising cancer cases, more diagnostic imaging, and stronger healthcare spending. North America held the largest share in 2025 and is expected to stay the fastest-growing region as precision oncology adoption deepens.

Why it matters: - Verluma is positioned in a growing corner of oncology diagnostics, where demand for earlier cancer detection and more precise imaging is rising. - The market’s momentum ties directly to higher cancer incidence, broader use of nuclear medicine, and more spending on diagnostic infrastructure. - The report frames Verluma as part of a larger shift toward precision oncology and companion diagnostics.

What happened: - The Business Research Company published its Verluma Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Verluma market is gaining attention as nuclear imaging and oncology diagnostics advance. - The report projects continued growth through 2035. - North America held the largest share of the Verluma market in 2025. - North America is expected to remain the fastest-growing regional market.

The details: - Verluma is a radiolabeled monoclonal antibody fragment used in nuclear medicine applications. - Verluma targets carcinoembryonic antigen, or CEA, a protein overexpressed in some cancers. - The imaging agent helps detect and stage cancers such as colorectal cancer. - The targeting supports visualization through imaging methods such as SPECT. - The report identifies rising cancer cases worldwide as a major growth driver. - The American Cancer Society reported about 313,510 new breast cancer cases in the U.S. in 2024, up from 300,590 in 2023. - Demand for diagnostic imaging procedures is also rising. - The National Health Service in England reported 45.0 million imaging tests by March 2023, up 2.2% from 44.0 million in 2022. - Growing healthcare expenditure is another support for the market. - The UK Office for National Statistics projected healthcare spending at £317 billion in 2024, a 6.5% nominal increase and a 2.4% real increase from 2023. - Long-term care expenditure in the UK rose 3.1% in real terms in 2023, driven mainly by higher government spending. - The report says growth is also supported by better access to radiopharmaceuticals, more oncology diagnostic infrastructure, and wider clinical acceptance of targeted imaging agents. - Other cited drivers include personalized cancer diagnostics, more nuclear medicine facilities, and the growing role of companion diagnostics. - The report also points to molecular imaging for cancer staging and innovations in radiolabeled antibody fragments. - Forecast trends include wider adoption of targeted radiolabeled diagnostics, greater use of CEA-targeted imaging agents, and broader application of nuclear medicine imaging.

Between the lines: - The report is not just describing one product niche. It is mapping a broader oncology diagnostics market that is becoming more data-driven and more treatment-linked. - North America’s lead suggests that advanced healthcare infrastructure and high cancer burden still matter more than early-stage cost sensitivity in this segment. - The emphasis on companion diagnostics points to a market where imaging tools are increasingly tied to therapy decisions, not just detection.

What's next: - The report expects demand to keep rising as cancer screening and precision oncology expand. - More investment in nuclear medicine facilities should support broader use of Verluma and similar agents. - The company says upcoming report updates include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The report also offers a free sample and the full market report via the company’s sample request page and the full market report.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

American Business Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

American Business Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.